29th-31st January 2018

Paris, France

2017 Speakers

Expand/Collapse

David Cook
Executive Vice President of Research & Development and
Chief Scientific Officer Seres Therapeutics

David Cook is the Executive Vice President of R&D and Chief Scientific Officer of Seres Therapeutics, Inc. ("Seres"). He has over 20 years of experience as a scientist and entrepreneur and has held senior operating and management positions in the biotechnology industry throughout his career. Prior to joining Seres, he served as the Chief Operating Officer for the International AIDS Vaccine Initiative (IAVI), a global R&D organization. Prior to IAVI, Dr. Cook was the founding CEO at Anza Therapeutics, a biotechnology startup that focused on developing a microbial vaccine platform to induce cellular immune responses. Before launching Anza, Dr. Cook held positions of increasing responsibility at the biotechnology corporations Cerus and Eligix, overseeing R&D, program management, manufacturing, and clinical and regulatory affairs. He has led teams in the development and commercialization of several biotech products and has been directly responsible for obtaining marketing authorization from the European Union for four medical products. Dr. Cook is also a co-inventor on more than 25 patents. He earned his undergraduate degree from Harvard College and his Ph.D. in chemistry from the University of California, Berkeley.

Day One

Wednesday 25th January, 2017

09.30 | Studying Microbiome-Host Interactions to Translate Microbiome Drugs into the Clinic

Isabelle De Cremoux
CEO
Seventure Partners

Isabelle is CEO and head of the Science Department of Life.Engineer from Ecole Centrale Paris, Isabelle brings to the team over 25 years of international experience in business development and finance in the pharmaceutical industry.She began her career in 1991 at Arthur Andersen in Detroit, USA, and then Pfizer Pfizer France and Europe where she held various positions for 6 years in the areas of management control, clinical research and business development.In 1998, she joined the Laboratoire Fournier / Abbott as assistant director of business development, responsible within the product and technology licensing group, as well as acquisitions, and has signed numerous transactions in Europe and the USA .She joined SEVENTURE in 2001 to create the Science department of life. Isabelle supervises the life sciences activity and personally invests live in France, Scandinavia and especially in biotech companies, nutrition, health, personalized medicine and especially in the field of microbiome.

Day One

Wednesday 25th January, 2017

09.00 | Perspectives on a Microbiome-Based Industry: How Far Are We From Science to Products?

Scott Parkinson
Head of Gastrointestinal Health and Microbiome
Nestle Institute of Health Sciences

Day Two

Thursday 26th January, 2017

13.40 | Lies, Damned Lies, Statistics and the Microbiome

Philippe Gerard
Team Leader, AMIPEM
INRA

Day One

Wednesday 25th January, 2017

15.00 | Using Germ-free Mouse Models to Modulate Liver Disease Development

James Brown
Director of Computational Biology
GSK

James Brown is Director of Computational Biology at GSK. James received his Ph.D. in Biology from Simon Faser University and is currently the head of the Microbiome Matrix Team which is leading the application of human microbiome studies to drug discovery at GSK.

Day One

Wednesday 25th January, 2017

15.30 | Panel Discussion: What Role Will Academic-Industrial Partnerships Play in Leveraging the Potential Success of Microbiome Therapeutics?

12.30 | Human-Microbe Interactions: A Drug Discovery Perspective

Luc Sterkman
CEO
Caelus Health

Day Two

Thursday 26th January, 2017

12.10 | Developing Microbiome Treatments for Cardio Metabolic Disease

Jean de Gunzberg
CSO
Da Volterra

Jean de Gunzburg graduated from “Ecole Agronomique de Paris” before becoming a molecular and cell biologist who after a highly successful academic carrier decided to devote his experience and know-how to the development of Da Volterra. After obtaining his Ph.D. in 1985 from the University of Paris 7 for work performed at the Institut Pasteur in Paris, Jean continued his training by a postdoctoral stay at the Whitehead Institute for Biomedical Research (Cambridge). He became in 1988 Research Director at the CNRS and headed the Laboratory for Signal Transduction and Oncogenesis of Inserm at the Institut Curie in Paris until mid 2005. He has published over 70 articles in international journals in fields ranging from Biochemistry and Molecular Biology to Cell biology. Jean de Gunzburg, as a seasoned scientist, brings to Da Volterra his wide expertise for conducting R&D programs, understanding finely at the molecular level diseases as well as drugs mode of action, developing adequate in vitro assays to model in vivo situations, optimizing both chemical and molecular analytical tools and biomarkers, and establishing in vivo proof of concept studies. Jean heads the R&D efforts of Da Volterra in close synergy with Antoine Andremont and Annie Ducher.

Day Two

Thursday 26th January, 2017

15.40 | DAV132: A Novel Product to Protect the Gut Microbiome During Antibiotic Treatment

Jean-Luc Treillous
CEO
Laboratories Nutrition et Cardmetabolisme (LNC)

PharmD, JLT started his career in Pharma industry with several industrial and controlling positions in GSK and Sanofi in Europe, Asia and Africa. Highly interested in Nutrition he became deputy GM of OENOBIOL, a 50 m€ Nutraceutical company. After various assignments as Venture Partner for EU-based VCs he’s been interim CEO of a Nutrition start-up for a 12 months mission. He joined LNC in 2011 as CEO.

Day One

Wednesday 25th January, 2017

16.30 | Seizing the Opportunity: Breakout Roundtables

Laurel Lagenaur
Director of Research
Osel Inc

Dr. Lagenaur is Osel’s first employee and has led development of Osel’s Lactobacillus technology platform as the Director of Research. She has been the principal investigator on numerous research grants, including Osel’s first SBIR grant to develop MucoCept-HIV as a novel live microbicide to prevent HIV transmission in women.Dr. Lagenaur is a molecular biologist with extensive experience in virology and bacteriology and was a clinical microbiologist in both the human and veterinary fields. She received her doctorate in Microbiology and Immunology from Stanford University, and completed a post-doctoral fellowship at the University of California, San Francisco.

Day Two

Thursday 26th January, 2017

11.40 | Engineering the Vaginal Microbiome to Restore Health and Prevent Infection- A Clinical Perspective

Lars Engstrand
Professor/Director
Karolinska Institutet / Center of Translational Microbiome Research (CTMR)

Day Two

Thursday 26th January, 2017

15.10 | Designing High Quality and Well Controlled Clinical Trials to Develop Novel Microbiome Therapeutics

Brian Varnum
Chief Development Officer
C3-Jian

Day One

Wednesday 25th January, 2017

13.00 | Development of Pathogen-Specific Antimicrobials to Restore Balance to the Human Microbiome

Kristin Wannerberger
Director of R&D Alliance Management
Ferring Pharmaceuticals

Day One

Wednesday 25th January, 2017

15.30 | Panel Discussion: What Role Will Academic-Industrial Partnerships Play in Leveraging the Potential Success of Microbiome Therapeutics?

Jens Nielsen
Professor Chalmers
University of Technology

Jens Nielsen has an MSc degree in Chemical Engineering and a PhD degree (1989) in Biochemical Engineering from the Danish Technical University (DTU), and after that established his independent research group and was appointed full Professor there in 1998. He was Fulbright visiting professor at MIT in 1995-1996. At DTU he founded and directed Center for Microbial Biotechnology. In 2008 he was recruited as Professor and Director to Chalmers University of Technology, Sweden, where he is currently directing a research group of more than 50 people. At Chalmers he established the Area of Advance Life Science Engineering, a cross departmental strategic research initiative and was founding Head of the Department of Biology and Biological Engineering, which now encompass more than 170 people. Jens Nielsen has published so far more than 550 papers that have been cited more than 35,000 times (current H-factor 92), and co-authored more than 40 books. He is inventor of more than 50 patents and he has founded several biotech companies. He has received numerous Danish and international awards including the Nature Mentor Award, and is member of several academies, including the National Academy of Engineering in USA, the Royal Swedish Academy of Science, the Royal Danish Academy of Science and Letters, the Royal Swedish Academy of Engineering Sciences and the American Academy of Microbiology. He is a founding president of the International Metabolic Engineering Society.

Day One

Wednesday 25th January, 2017

14.30 | A Systems Biology Approach to Measuring Human-Microbiome Interactions

Trevor Lawley
Trevor Lawley Group Leader
Wellcome Trust Sanger Institute

Trevor uses high-throughput genome sequencing to investigate the microbial communities contained on and within host organisms that are associated with health and disease. He uses clinical samples and mouse models to identify the pathogen and host factors that are linked to disease and infectivity.Trevor obtained his PhD from the University of Alberta, Canada, where he studied the mechanisms that pathogenic bacteria use to disseminate antibiotic resistance genes. Dr Diane Taylor and Dr Laura Frost were his supervisors. His PhD thesis culminated in 2004 with him receiving the 'Gold Award' (Graduate Student of the Year) from the Canadian Society of Microbiologists. After his PhD Trevor was awarded a Canadian Institutes of Health Research post-doctoral fellowship to work in the Laboratory of Professor Stanley Falkow and Dr Denise Monack at Stanford University, USA, where he studied the impact of antibiotic treatment on Salmonella disease and transmission. In 2007 Trevor received a Royal Society of London Award - sponsored by Professor Gordon Dougan - to start a research programme on Clostridium difficile disease and transmission within the Microbial Pathogenesis group at the Wellcome Trust Sanger Institute.

Herve Affagard
CEO
Maat Pharma

Hervé leads the MaaT Pharma project since its inception phase in December 2013. Hervé worked previously as an entrepreneur in residence for venture capital firms with regards to their investments in the Healthcare field. In parallel, he also used to work as a consultant for biotechnology companies where he led transformation program. He was previously an executive director leading a multidisciplinary team at Biomnis, specialist in medical testing. Combined with his previous experience at Bio-Rad which serves life science research and clinical diagnostics customers, he brings to MaaT Pharma a strong track record of operational leadership in the health sector and the capacity to translate into a concrete plan medical notions. Hervé is also a result-oriented person who led successfully projects up to €50m.

Day One

Wednesday 25th January, 2017

15.30 | Panel Discussion: What Role Will Academic-Industrial Partnerships Play in Leveraging the Potential Success of Microbiome Therapeutics?

Day Two

Thursday 26th January, 2017

14.10 | MaaT Pharma: Rebuilding a Natural Ecosystem with Autologous Fecal Microbiota Transfer

Xavier Durportet
CEO
Eligo Biosciences

Day Two

Thursday 26th January, 2017

09.30 | Using Synthetic Biology for Targeted Antimicrobials & Microbiome Engineering

Brian Goodman
Head of Scientific Strategy
Evelo Biosciences

Nicholas Monsul
CEO
Quorum Innovations

Dr. Monsul was born in Philadelphia and graduated from Drexel University.  He completed his medical degree at Hahnemann University, Drexel University College of Medicine.  His ophthalmology residency at Yale University was followed by fellowship programs at The Johns Hopkins Hospital, The Wilmer Eye Institute and Allegheny General Hospital in Pittsburgh.  He moved to Florida in 2003.  Throughout his career and education, he has been involved in basic science research with a particular interested in neural regeneration and neuronal cell death.  In addition to his roles at Quorum Innovations where he is actively involved in the research program, he is a surgeon with a busy practice in the Hawthorne Clinic and Research Center.

Day Two

Thursday 26th January, 2017

11.10 | Translational Research in Developing Skin Microbiome Therapeutics

Bruce Roberts
CSO
Vedanta Biosciences

Dr. Roberts is the Chief Scientific Officer at Vedanta Biosciences. Previously he was Head of Neuro-Immunology and Immune-Mediated Disease Research at Sanofi Genzyme. Dr. Roberts has 30 years experience in biotech/pharma  and directed efforts resulting in the introduction of therapeutic antibodies, gene therapies, cell therapies and small molecules into clinical trials for the treatment of cancer, multiple sclerosis and autoimmunity.

Day Two

Thursday 26th January, 2017

09.00 | Generation and Development of Defined Microbial Drug Products

Philippe Lenee
Director of Partnerships and Technology Transfer
INRA

Dr Philippe Lénée, PhD in biotechnology and agronomy engineer has twelve years of experience in research in biotechnology in a private seed company and four years of executive management as operations director of a food factory. In 2003, he was CEO of INRA Transfert, the INRA subsidiary in charge of technology transfer of innovations and management of European R&D projects. In November 2015, Philippe Lénée became director of public/private partnerships and technology transfer of the French National Institute for Agricultural Research (INRA). His responsibilities encompassed: technology transfer and commercialization of INRA innovations, creation of start-up from INRA results, business intelligence and R&D partnerships with industry in the economic sectors of health and food safety, animal health, food, plant and animal production, environment and animal and plant biotechnology. The INRA portfolio counted 570 research contracts with private bodies, 350 patents families and 420 active licenses of patent, know-how and software exploitation for an annual turnover of royalties over 4 M€.

Day One

Wednesday 25th January, 2017

15.30 | Panel Discussion: What Role Will Academic-Industrial Partnerships Play in Leveraging the Potential Success of Microbiome Therapeutics?

John Hambor
Director, Research Beyond Borders
Boehringer Ingelheim

Day One

Wednesday 25th January, 2017

16.30 | Seizing the Opportunity: Breakout Roundtables

Henrik Bjorn Nielsen
CSO
Clinical Microbiomics

H. Bjørn Nielsen, PhD, Chief Scientific Officer at Clinical-Microbiomics, has since 2008 been a frontrunner in the field of microbiome research. His participation in the MetaHit consortium led to a series of important scientific papers describing the human gut microbiome, including his pioneering work on co-abundance binning of metagenomics data into metagenomic species, bacteriophages and other mobile genetic elements, and this year Henrik have authored 4 papers published in Nature journals, including a three-pronged association study that links microbiome, serum metabolome and clinical data in pre-diabetic Danes and a study that report on the larges metatranscriptomics to date. At Clinical-Microbiomics H. Bjørn heads the innovation with clients and the continued adaptation and development of new analysis concepts and methods.

Day One

Wednesday 25th January, 2017

10.30 | Microbial Adaptations of the Microbiome

Emilie Plantamura
Clinical Project Manager
MaaT Pharma

Workshop A

Tuesday 24th January, 2017

09.00 | Past, Present and Future Applications: How to use FMT to Fight Disease?

Harry Sokol
Professor of Gastroenterology
Assistance Publique-Hopitaux De Paris

Workshop A

Tuesday 24th January, 2017

09.00 | Past, Present and Future Applications: How to use FMT to Fight Disease?

Joseph Petrosino
Founder and CSO
Diversigen, Inc

Dr. Petrosino is an Associate Professor of Molecular Virology and Microbiology at Baylor College of Medicine (BCM) where he is also the director of the Alkek Center for Metagenomics and Microbiome Research.  In partnership with BCM Technologies, Dr. Petrosino founded Diversigen Inc., which provides commercially targeted microbiome sequencing and analysis, along with other specialized services, to the clinical and animal health sectors.

Day One

Wednesday 25th January, 2017

12.00 | Where the Microbiome Will Matter for the Pharmaceutical Industry and Why

Larry Weiss
CMO
AOBiome

Workshop B

Tuesday 24th January, 2017

13.00 | Pharmaceutical OR Consumer Product? Re-Writing the Rules for Microbiome Therapies

Day Two

Thursday 26th January, 2017

10.40 | Manipulating Complex Biological Systems Using Microorganisms

Dirk Gevers
Global Head, Janssen Human Microbiome Institute
Janssen R&D

Mohan Iyer
Chief Business Officer
Second Genome, Inc.

Workshop B

Tuesday 24th January, 2017

13.00 | Pharmaceutical OR Consumer Product? Re-Writing the Rules for Microbiome Therapies

Djamel Deken
Business Development Manager
SynCo Bio Partners B.V.

Day Two

Thursday 26th January, 2017

10.00 | Human Microbiota: Proof of Concept to Production

Johan Vlieg
VP, Microbiome and Human Health Innovation
Chr. Hansen

Workshop B

Tuesday 24th January, 2017

13.00 | Pharmaceutical OR Consumer Product? Re-Writing the Rules for Microbiome Therapies

Jai Patel
Chief Medical Officer
Enterome

Day One

Wednesday 25th January, 2017

10.00 | EB8010 – A Novel Therapeutic Approach Targeting the Microbiome in Patients With Crohn’s Disease.